Literature DB >> 34677796

Emerging Epigenetic Therapies for Brain Tumors.

Lokesh Kukreja1, Catherine J Li1, Sathyapriya Ezhilan1, Vishwanath R Iyer2, John S Kuo3,4.   

Abstract

Malignant brain tumors are among the most intractable cancers, including malignancies such as glioblastoma, diffuse midline glioma, medulloblastoma, and ependymoma. Unfortunately, treatment options for these brain tumors have been inadequate and complex, leading to poor prognoses and creating a need for new treatment modalities. Aberrant epigenetics define these types of tumors, with underlying changes in DNA methylation, histone modifications, chromatin structure and noncoding RNAs. Epigenetic-targeted therapies are an alternative that have the potential to reverse the epigenetic deregulation underpinning brain malignancies. Various drugs targeting epigenetic regulators have shown promise in preclinical and clinical testing. In this review, we highlight some of the recent emerging epigenetic targeted therapies for brain tumors being evaluated in the discovery phase and in clinical trials.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Brain tumors; Clinical trials; Epigenetic; Mechanisms

Mesh:

Year:  2021        PMID: 34677796     DOI: 10.1007/s12017-021-08691-x

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  50 in total

Review 1.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

Review 2.  Non-coding RNAs in human disease.

Authors:  Manel Esteller
Journal:  Nat Rev Genet       Date:  2011-11-18       Impact factor: 53.242

Review 3.  MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells.

Authors:  Jeffrey V Brower; Paul A Clark; Will Lyon; John S Kuo
Journal:  Neurochem Int       Date:  2014-06-14       Impact factor: 3.921

Review 4.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 5.  Signal Transduction in Diffuse Intrinsic Pontine Glioma.

Authors:  Ryan J Duchatel; Evangeline R Jackson; Frank Alvaro; Brett Nixon; Hubert Hondermarck; Matthew D Dun
Journal:  Proteomics       Date:  2019-08-14       Impact factor: 3.984

6.  Identification of microRNAs as potential prognostic markers in ependymoma.

Authors:  Fabricio F Costa; Jared M Bischof; Elio F Vanin; Rishi R Lulla; Min Wang; Simone T Sredni; Veena Rajaram; Maria de Fátima Bonaldo; Deli Wang; Stewart Goldman; Tadanori Tomita; Marcelo B Soares
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

Review 7.  The microRNA-183 cluster: the family that plays together stays together.

Authors:  Shweta Dambal; Mit Shah; Brittany Mihelich; Larisa Nonn
Journal:  Nucleic Acids Res       Date:  2015-07-13       Impact factor: 16.971

8.  5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.

Authors:  Alexandra Borodovsky; Vafi Salmasi; Sevin Turcan; Armida W M Fabius; Gilson S Baia; Charles G Eberhart; Jon D Weingart; Gary L Gallia; Stephen B Baylin; Timothy A Chan; Gregory J Riggins
Journal:  Oncotarget       Date:  2013-10

9.  microRNA-100 targets SMRT/NCOR2, reduces proliferation, and improves survival in glioblastoma animal models.

Authors:  Bahauddeen M Alrfaei; Raghu Vemuganti; John S Kuo
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

10.  Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma.

Authors:  Harish Shrikrishna Bharambe; Annada Joshi; Kedar Yogi; Sadaf Kazi; Neelam Vishwanath Shirsat
Journal:  Acta Neuropathol Commun       Date:  2020-05-14       Impact factor: 7.801

View more
  1 in total

Review 1.  Cell-of-Origin and Genetic, Epigenetic, and Microenvironmental Factors Contribute to the Intra-Tumoral Heterogeneity of Pediatric Intracranial Ependymoma.

Authors:  Tiziana Servidei; Donatella Lucchetti; Pierluigi Navarra; Alessandro Sgambato; Riccardo Riccardi; Antonio Ruggiero
Journal:  Cancers (Basel)       Date:  2021-12-03       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.